Baird lowered the firm’s price target on Charles River to $190 from $191 and keeps a Neutral rating on the shares. In the firm’s Q2 Contract Research Organization, or CRO, quarterly review and outlook note, the analyst says “fundamentals weakened, tone shifted, confusion reigned supreme since Q2.” However, Baird adds that “September changed the narrative, keeping us on board into earnings.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRL:
- Charles River announces collaboration with DanubeNeuro acceleration program
- Charles River, Insightec team on therapy in neuroscience with FUS
- Charles River price target lowered to $203 from $228 at TD Cowen
- Charles River price target lowered to $215 from $235 at Morgan Stanley
- Charles River price target lowered to $240 from $300 at Deutsche Bank